Around the world, researchers are working extremely hard to develop new treatments and interventions for COVID-19 with new clinical trials opening nearly every day. This directory provides you with information, including enrollment detail, about these trials. In some cases, researchers are able to offer expanded access (sometimes called compassionate use) to an investigational drug when a patient cannot participate in a clinical trial.
The information provided here is drawn from ClinicalTrials.gov. If you do not find a satisfactory expanded access program here, please search in our COVID Company Directory. Some companies consider expanded access requests for single patients, even if they do not show an active expanded access listing in this database. Please contact the company directly to explore the possibility of expanded access.
Emergency INDs
To learn how to apply for expanded access, please visit our Guides designed to walk healthcare providers, patients and/or caregivers through the process of applying for expanded access. Please note that given the situation with COVID-19 and the need to move as fast as possible, many physicians are requesting expanded access for emergency use. In these cases, FDA will authorize treatment by telephone and treatment can start immediately. For more details, consult FDA guidance. Emergency IND is the common route that patients are receiving convalescent plasma.
Search Tips
To search this directory, simply type a drug name, condition, company name, location, or other term of your choice into the search bar and click SEARCH. For broadest results, type the terms without quotation marks; to narrow your search to an exact match, put your terms in quotation marks (e.g., “acute respiratory distress syndrome” or “ARDS”). You may opt to further streamline your search by using the Status of the study and Intervention Type options. Simply click one or more of those boxes to refine your search.
Displaying 220 of 530Instituto de Medicina Regenerativa
This is a pilot phase, open label, non-randomized study for the treatment of ARDS inpatients infected with COVID-19. Subjects will be enrolled and treated with one dose ofmesenchymal stem cells and follow-up will occur 90 days post-treatment.
Wuhan Union Hospital, China
The intent of this study was to examine the health status of individuals who had beenconfirmed with COVID-19 in the year after their recovery. Parameters studied includedserum levels of SARS coronavirus 2 (SARS-CoV 2) IgG antibody, SARS-CoV-2 nucleic acidtest, hematology indicators (blood routine, liver function, kidney function, myocardialenzymes, coagulation function, etc), lung function test, imaging data and airwaymicrobiota data. In addition, we explored the systematic Immune & Inflammation in some ofthe individuals recovering from COVID-19.
Johns Hopkins University
The investigators aim to deliver a tele-wellness supported app to Baltimore City's FamilyChild Care Home (FCCH) providers who are caring for children of Essential Personnel. Oncea pre-survey is conducted, login information will be assigned to 30 Family Child CareHome providers and parents the FCCH serve. Providers and Parents will receive self-careand parenting/parent engagement support through the app and through a tele-wellnessservice, Ask a Nurse, provided by community health nurses at the Johns Hopkins School ofNursing. Children will have access to gamified learning materials in early literacy,math, social-emotional learning, and nutrition.
Deborah O'Connor
The Canadian Paediatric Society recommends breastfeeding during COVID-19 infection. Humanmilk is the best form of infant nutrition providing significant protection against manyillnesses for term and preterm infants. When mothers of hospitalized infants are unableto supply their milk, the recommended supplement is human donor milk. The impact of apandemic on human milk banking is unknown. This study seeks to address this public healthissue. Donor milk will be collected from the Rogers Hixon Ontario Human Milk Bank atSinai Health System in Toronto. Samples will be analyzed for the COVID-19 virus specificnucleic acid and antibody in real-time and results will be immediately disseminated torelevant organizations to inform local, national and international guidelines surroundingdonor milk banking to protect the health of infants.
Deborah O'Connor
The Canadian Paediatric Society recommends breastfeeding during COVID-19 infection. Humanmilk is the best form of infant nutrition providing significant protection against manyillnesses for term and preterm infants. The impact of a pandemic on breastfeeding isunknown. This study seeks to address this public health issue. Breastmilk will becollected from mothers positive for COVID-19. Samples will be analyzed for the COVID-19virus specific nucleic acid and antibody in real-time and results will be immediatelydisseminated to relevant organizations to inform local, national and internationalguidelines surrounding breastfeeding to protect the health of infants.
Biomed Industries, Inc.
This Phase 2/3 trial evaluates four treatment strategies for non-critically illhospitalized participants (not requiring ICU admission and/or mechanical ventilation)with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir withor without Dexamethasone.
Baylx Inc.
This is a phase 1/2a study including 2 parts, phase 1 and phase 2a. The phase 1 part isan open-label, single-arm, dose-escalating study to evaluate the safety and explore thedose limiting toxicity and maximum tolerated dose of a human umbilical cord derivedmesenchymal stem cell product (BX-U001) in severe COVID-19 pneumonia patients with acuterespiratory distress syndrome (ARDS). Qualified subjects after the screening will bedivided into low, medium, or high dose groups to receive a single intravenous infusion ofBX-U001 at the dose of 0.5×10^6, 1.0×10^6, or 1.5×10^6 cells/kg of body weight,respectively. The Phase 2a part is a randomized, placebo-controlled, double-blindclinical trial examining the safety and biological effects of BX-U001 at the appropriatedose selected from phase 1 for severe COVID-19 pneumonia patients with the sameinclusion/exclusion criteria as the phase 1 part.
Imagine Institute
This is a European observational cohort study (data research) involving multiple centresto look at the potential impact of COVID infection on patients with rare skin diseasesexamining factors such as comorbidity, protection factors, and clinical and/ortherapeutic factors. The data collected may provide additional information on thesituation of patients and, on a wider basis, provide useful data applicable to thegeneral population.
Swiss School of Public Health (SSPH+)
There is a lack of knowledge about how many children are infected with SARS-CoV-2, howoften they are asymptomatic, and how long the immunity persists.The main purpose of this study is to measure antibodies to SARS-CoV-2, symptoms, and riskfactors in a representative cohort of children and adolescents in the canton of Zurich,Switzerland, shortly after re-opening of the school system and thereafter. The study alsoinvestigates antibodies to SARS-CoV-2 in parents of the children and school personnel.
National Cancer Institute (NCI)
This study uses questionnaires to gain an understanding of how experiences during theCOVID-19 pandemic, regardless of COVID-19 status, may have impacted health-relatedquality of life (HRQOL) and other areas such as COVID-19-specific psychological distress,disruptions to health care, finances and social interactions in cancer patients. Thecoronavirus disease 2019 (COVID-19) is an infectious disease that is caused by the severeacute respiratory syndrome coronavirus 2 (SARS-CoV-2). The information learned from thisstudy will guide the development of psychosocial programs to improve patient care andoutcomes in cancer patients and survivors in the context of facing a global pandemic.